T cell redirecting bispecific antibodies (Scancell)

N/A

Report date: 2026/03/19 16:57:21

Base Information

Drug NameT cell redirecting bispecific antibodies (Scancell)
Drug Alias NameT cell redirecting bispecific antibodies (Scancell)
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers
Mechanisms of ActionT cell surface glycoprotein CD3 modulators
TargetsT cell surface glycoprotein CD3
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited Kingdom
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesScancell Ltd
China Registration ClassN/A

Develop Information

Active CompaniesScancell Ltd
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A